Clinical trial · Interventional
Promoting Informed Choice for Breast Cancer Screening
Understanding Affective Processing of Scientific Evidence to Promote Informed Choice for Breast Cancer Screening
NCT05376241CI-TRIAL-00106670completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Identify the prevalence and predictors of reactance, self-exemption, disbelief, source derogation in reaction to evidence about mammography benefits and harms, and consequences for decision-making and trust.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Decision aid | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Women age 39-49 in the United States
- description
- The group is women age 39-49 in the United States who receive a decision aid intervention. The intervention is a breast cancer screening decision aid with information about screening guidelines, breast cancer mortality reduction, false positives, overdiagnosis, and a personal breast cancer risk estimate.
- interventionNames
- Behavioral: Decision aid
Primary outcomes (5)
- measure
- Reactance
- timeFrame
- 24 hours
- description
- In response to mammography evidence, feeling that the information is manipulative or biased. 4 questions total, each on a 7 point Likert scale, with mean scores that range from 1 to 5. Higher mean scores reflect greater reactance.
- measure
- Disbelief
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 39 Years
- Maximum age
- 49 Years
Show eligibility criteria text
Inclusion Criteria: * Female * Between 39-49 years of age * No history of breast cancer * No known BRCA 1/2 mutation Exclusion Criteria: * Non-English or Spanish Speaking * Persons unable to provide informed consent (e.g. sever dementia or cognitive disability or illiterate * History of breast cancer * Known BRCA 1/2 mutation
References
Publications (4)
- BACKGROUNDScherer LD, Lewis CL, Cappella JN, Hersch J, McCaffery K, Tate C, Smyth HL, Mosley B, Morse B, Schapira MM. Skeptical reactions to breast cancer screening benefits and harms: Antecedents, consequences, and implications for screening communication. Health Psychol. 2025 Jun;44(6):608-619. doi: 10.1037/hea0001442. Epub 2024 Nov 25. PMID 39585772
- BACKGROUNDScherer LD, Lewis CL, McCaffery K, Hersch J, Cappella JN, Tate C, Morse B, Arnett K, Mosley B, Smyth HL, Schapira MM. Mammography Screening Preferences Among Screening-Eligible Women in Their 40s : A National U.S. Survey. Ann Intern Med. 2024 Aug;177(8):1069-1077. doi: 10.7326/M23-3325. Epub 2024 Jul 16. PMID 39008858
- BACKGROUNDParmet T, Yoder G, Morse B, Cappella J, Schapira M, Lewis C, McCaffery K, Smyth H, Hersch J, Scherer LD. Trust in the healthcare system declines after exposure to information about the harms and benefits of breast cancer screening. J Health Psychol. 2025 Nov;30(13):4091-4097. doi: 10.1177/13591053251315383. Epub 2025 Feb 7. PMID 39917819
- RESULTMorse B, Parmet T, Yoder G, Tate CE, Lewis CL, McCaffery K, Cappella JN, Hersch J, Schapira MM, Scherer LD. Evaluation of how US women react to a decision aid informing them of the harms and benefits of mammography: a qualitative study. BMJ Open. 2025 Mar 18;15(3):e087997. doi: 10.1136/bmjopen-2024-087997. PMID 40107692